ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with (18)F-FDG PET and Correlation with Genotype and GLUT4 Expression

We investigated the correlation between metabolic response by (18)F-FDG PET and objective response, glucose transporter type 4 (GLUT4) expression, and KIT/PDGFRA mutation status in patients with gastrointestinal stromal tumor undergoing neoadjuvant imatinib mesylate therapy. METHODS: (18)F-FDG PET w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Van den Abbeele, Annick D., Gatsonis, Constantine, de Vries, Daniel J., Melenevsky, Yulia, Szot-Barnes, Agnieszka, Yap, Jeffrey T., Godwin, Andrew K., Rink, Lori, Huang, Min, Blevins, Meridith, Sicks, JoRean, Eisenberg, Burton, Siegel, Barry A.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3635677/
https://ncbi.nlm.nih.gov/pubmed/22381410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.111.094425
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares